Imperial College London

ProfessorPatrickSerruys

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.serruys

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kukreja:2008:10.1016/j.phrs.2008.01.012,
author = {Kukreja, N and Onuma, Y and Daemen, J and Serruys, PW},
doi = {10.1016/j.phrs.2008.01.012},
journal = {Pharmacol Res},
pages = {171--180},
title = {The future of drug-eluting stents.},
url = {http://dx.doi.org/10.1016/j.phrs.2008.01.012},
volume = {57},
year = {2008}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - This review aims to provide a glimpse into the future of drug-eluting stents (DES). Since their arrival in 2002, DES have transformed the practice of interventional cardiology by drastically reducing restenosis and the need for repeat revascularization. However, data about the potentially fatal long-term risk of stent thrombosis have spurred on research and development to improve upon the first generation of devices. The initial commercially available DES used a stainless steel platform coated with a permanent polymer to provide controlled release of the anti-restenotic drug. The platform, polymer and drug are all targets for improvement. More advanced metallic and fully biodegradable stent platforms are currently under investigation. The permanent polymer coating, a likely contributor adverse events, is being superseded by biocompatible and bioabsorbable alternatives. New drugs and drug combinations are also a research goal, as interventional cardiologists and the industry strive towards safer anti-restenotic DES.
AU - Kukreja,N
AU - Onuma,Y
AU - Daemen,J
AU - Serruys,PW
DO - 10.1016/j.phrs.2008.01.012
EP - 180
PY - 2008///
SN - 1043-6618
SP - 171
TI - The future of drug-eluting stents.
T2 - Pharmacol Res
UR - http://dx.doi.org/10.1016/j.phrs.2008.01.012
UR - https://www.ncbi.nlm.nih.gov/pubmed/18339557
VL - 57
ER -